Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy

XF Li, S Carlin, M Urano, J Russell, CC Ling… - Cancer research, 2007 - AACR
XF Li, S Carlin, M Urano, J Russell, CC Ling, JA O'Donoghue
Cancer research, 2007AACR
Tumor hypoxia is commonly observed in primary solid malignancies but the hypoxic status
of subclinical micrometastatic disease is largely unknown. The distribution of hypoxia in
microscopic tumors was studied in animal models of disseminated peritoneal disease and
intradermal (id) growing tumors. Tumors derived from human colorectal adenocarcinoma
cell lines HT29 and HCT-8 ranged in size from a few hundred microns to several millimeters
in diameter. Hypoxia was detected by immunofluorescent visualization of pimonidazole and …
Abstract
Tumor hypoxia is commonly observed in primary solid malignancies but the hypoxic status of subclinical micrometastatic disease is largely unknown. The distribution of hypoxia in microscopic tumors was studied in animal models of disseminated peritoneal disease and intradermal (i.d.) growing tumors. Tumors derived from human colorectal adenocarcinoma cell lines HT29 and HCT-8 ranged in size from a few hundred microns to several millimeters in diameter. Hypoxia was detected by immunofluorescent visualization of pimonidazole and the hypoxia-regulated protein carbonic anhydrase 9. Tumor blood perfusion, cellular proliferation, and vascularity were visualized using Hoechst 33342, bromodeoxyuridine, and CD31 staining, respectively. In general, tumors of <1 mm diameter were intensely hypoxic, poorly perfused, and possessed little to no vasculature. Larger tumors (∼1–4 mm diameter) were well perfused with widespread vasculature and were not significantly hypoxic. Patterns of hypoxia in disseminated peritoneal tumors and i.d. tumors were similar. Levels of hypoxia in microscopic peritoneal tumors were reduced by carbogen breathing. Peritoneal and i.d. tumor models are suitable for studying hypoxia in microscopic tumors. If the patterns of tumor hypoxia in human patients are similar to those observed in these animal experiments, then the efficacy of systemic treatments of micrometastatic disease may be compromised by hypoxic resistance. [Cancer Res 2007;67(16):7646–52]
AACR